Dr. Beth Seidenberg has medicine in her blood. From standing on a stool as a child watching her father conducting heart surgery, to her groundbreaking work developing new treatments for AIDS and cancer, she’s spent most of her life immersed in the field. Throughout her career, Seidenberg has made an indelible impact on science and medicine as both a clinician and a researcher. Today, her focus is to empower the next generation of visionaries through her leadership in life sciences investing.
As a founding managing director of Westlake Village BioPartners, general partner at Kleiner Perkins, and numerous other endeavors, Seidenberg has incubated and invested in more than 40 biotech ventures since 2005. Among many others, they include ARMO Biosciences, Arresto Biosciences, Arsenal Biosciences, Atara Biotherapeutics, Cell Design Labs, Epizyme, Flexus Biosciences, iPierian, Kyverna Therapeutics, Livongo Health, Neuron23, Progyny, RAPT Therapeutics, Tesaro, Tmunity Therapeutics, and True North Therapeutics.
Seidenberg was awarded the 2022 Healthcare Businesswomen’s Association “Woman of the Year” Award.
As a co-founding managing director of Westlake Village BioPartners, Seidenberg believes this is the Golden Age of Biotech. “The pace and quality of innovation have hit an inflection point,” she explains. “With Westlake Village BioPartners we have the freedom and expertise to turn the next big technologies into products and companies that benefit human health.”
Seidenberg looks for entrepreneurs who have a clear vision and passion for what they are doing and why they are doing it. Her advice to entrepreneurs: “Focus on an important unmet medical need and find a seasoned, quality mentor and investor to help guide you through the company-building process.”
Since 2018, Westlake Village BioPartners has raised more than $820 million, investing in and incubating 20 life sciences companies, with more than half in the Los Angeles area. Seidenberg’s vision for the firm is to become one of the top biotech investors in the country and establish Los Angeles as a major biotech hub.
Seidenberg’s understanding of human health at the genetic, cellular, and systemic levels also has helped her envision new forms of delivering healthcare. Through her investment in Livongo, Seidenberg has helped reimagine the management and delivery of care to patients with diabetes, hypertension and other chronic diseases. The acquisition of Teladoc now broadens that opportunity for patients.
Progyny, another of Seidenberg’s investments, has redesigned the delivery of fertility benefits for patients who desire to start a family. They have applied cutting-edge science and technology to ensure employers receive the most value from their fertility benefit by enabling members and physicians to focus on superior clinical outcomes and pursue the most effective treatment, shortening the time to pregnancy.
As a venture capitalist, for Seidenberg it’s not just about bringing new medicines to patients. That is her core mission, but these new companies also provide jobs and shareholder value that benefit society more broadly. Her energy and attention to detail coupled with her drive to improve human health prove valuable assets in the complex and multifaceted world of being a venture capitalist.
Prior to life science investing, Seidenberg’s career focused on developing new treatments for AIDS, arthritis, asthma, cancer and psoriasis, cardiovascular, metabolic, neurological and renal disorders for over 20 years. During that time, she introduced 10 innovative products to market.
Seidenberg holds a Bachelor of Arts degree in biology and anthropology from Barnard College and attended medical school at the University of Miami School of Medicine. She completed her medical residency at Johns Hopkins University and George Washington University, and Fellowship at the National Institutes of Health.